By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

New QOF indicators added to menu by NICE

By Editor
18th October 2018
Guidelines, NHS England NICE

An update of the QOF indicator list for 2019/20 features eight new diabetes indicators, NICE has confirmed.

The new approach, which comes following a review of the QOF in England, will improve outcomes and decrease the risk of harm from over-treatment, the organisation said.

Professor Gillian Leng, Deputy Chief Executive of NICE, said: “A number of the new NICE indicators for people with diabetes take account of frailty and are a step towards helping enable the greater personalisation of care. The intent of these indicators is to reduce the risk of treatment-related harm and improve the quality of life for people with moderate or severe frailty.”

Updated indicators on type 2 diabetes include two indicators on blood glucose targets for people with and without frailty, while another sets one blood pressure target for all people without frailty.

Meanwhile, three new indicators feature which have been added since the consultation draft, supporting existing NICE recommendations on cardiovascular risk assessments and statin treatment for people with type 2 diabetes.

These new indicators will be support negotiations for the content of the 2019/20 QOF, which is determined through negotiations between NHS England and the General Practitioners Committee (GPC) of the British Medical Association (BMA).

The indicators 

  • NM157 – The percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 58mmol/mol or less in the preceding 12 months.
  • NM158 – The percentage of patients with diabetes with moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 75mmol/mol or less in the preceding 12 months.
  • NM159 – The percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80mmHg or less.
  • NM142 – The percentage of patients with type 1 diabetes who are aged over 40 years currently treated with a statin.
  • NM160 – The percentage of patients aged 25-84 years, with a diagnosis of type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a cardiovascular risk assessment using a risk assessment tool agreed with the NHS Commissioning Board in the last three years.
  • NM161 – The percentage of patients with a diagnosis of type 2 diabetes and a recorded CVD risk assessment score of ≥10% (without moderate or severe frailty), who are currently treated with a statin (unless there is a contraindication or statin therapy is declined).
  • NM162 – The percentage of patients with diabetes aged 40 years and over, with no history of CVD and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a CVD risk score of <10% recorded in the preceding 3 years).
  • NM163 – The percentage of patients with diabetes and a history of CVD (excluding haemorrhagic stroke) who are currently treated with a statin.

Comments (0)

Register an account or login to comment